173 related articles for article (PubMed ID: 32253072)
1. Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China.
Wang C; Bai Y; Li R; Shen C; Zhang J
Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115039. PubMed ID: 32253072
[TBL] [Abstract][Full Text] [Related]
2. Simulation of antibiotic pharmacodynamic exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program.
Maglio D; Kuti JL; Nicolau DP
Clin Ther; 2005 Jul; 27(7):1032-42. PubMed ID: 16154482
[TBL] [Abstract][Full Text] [Related]
3. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
Kim A; Kuti JL; Nicolau DP
Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Ceftazidime/Avibactam Administration in
Dai Y; Chang W; Zhou X; Yu W; Huang C; Chen Y; Ma X; Lu H; Ji R; Ying C; Wang P; Liu Z; Yuan Q; Xiao Y
Drug Des Devel Ther; 2021; 15():2899-2905. PubMed ID: 34262257
[TBL] [Abstract][Full Text] [Related]
5. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
[TBL] [Abstract][Full Text] [Related]
6. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
7. Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Jang SM; Lewis SJ; Rhie SJ
J Crit Care; 2022 Dec; 72():154172. PubMed ID: 36270240
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
[TBL] [Abstract][Full Text] [Related]
9. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
10. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
Ellis JM; Kuti JL; Nicolau DP
Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/Pharmacodynamic Modeling of Seven Antimicrobials for Empiric Treatment of Adult Bloodstream Infections with Gram-Negative Bacteria in China.
Wang C; Hao W; Jin Y; Shen C; Wang B
Microb Drug Resist; 2020 Dec; 26(12):1559-1567. PubMed ID: 31794682
[No Abstract] [Full Text] [Related]
13. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
14. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.
Eagye KJ; Nicolau DP; Lockhart SR; Quinn JP; Doern GV; Gallagher G; Abramson MA
Ann Clin Microbiol Antimicrob; 2007 Oct; 6():11. PubMed ID: 17908321
[TBL] [Abstract][Full Text] [Related]
15. Evaluating empiric treatment options for secondary peritonitis using pharmacodynamic profiling.
Eagye KJ; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2007 Apr; 8(2):215-26. PubMed ID: 17437367
[TBL] [Abstract][Full Text] [Related]
16. Application of Pharmacodynamic Profiling for the Selection of Optimal β-lactam Regimens in a Large University Hospital.
Koomanachai P; Yungyuen T; Disthaporn P; Kiratisin P; Nicolau DP
Int J Infect Dis; 2016 May; 46():22-6. PubMed ID: 27021531
[TBL] [Abstract][Full Text] [Related]
17. Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation.
Ito A; Tatsumi Y; Wajima T; Nakamura R; Tsuji M
Jpn J Antibiot; 2014 Apr; 67(2):109-22. PubMed ID: 24956910
[TBL] [Abstract][Full Text] [Related]
18. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.
Kuti JL; Dandekar PK; Nightingale CH; Nicolau DP
J Clin Pharmacol; 2003 Oct; 43(10):1116-23. PubMed ID: 14517194
[TBL] [Abstract][Full Text] [Related]
19. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.
Cheatham SC; Shea KM; Healy DP; Humphrey ML; Fleming MR; Wack MF; Smith DW; Sowinski KM; Kays MB
Int J Antimicrob Agents; 2011 Jan; 37(1):46-50. PubMed ID: 21074370
[TBL] [Abstract][Full Text] [Related]
20. Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysis.
Shi Q; Huang C; Chen W; Wu S; Ji J; Ying C; Wu H; Xiao Y
Eur J Pharm Sci; 2023 Jan; 180():106334. PubMed ID: 36402309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
